Global Proton Pump Inhibitors (PPIs) Market 2024-2028
The proton pump inhibitors (PPIs) market is forecasted to grow by USD 807.89 mn during 2023-2028, accelerating at a CAGR of 4.86% during the forecast period. The report on the proton pump inhibitors (PPIs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by reformulation of drugs, growth in prescription rate, and strong prevalence of gastroesophageal reflux disease.
Technavio's proton pump inhibitors (PPIs) market is segmented as below:
By Product
- OTC PPIs
- Prescription PPIs
By Route Of Administration
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the growing geriatric population as one of the prime reasons driving the proton pump inhibitors (PPIs) market growth during the next few years. Also, rising prevalence of obesity and personalized PPI therapy will lead to sizable demand in the market.
The report on the proton pump inhibitors (PPIs) market covers the following areas:
- Proton pump inhibitors (PPIs) market sizing
- Proton pump inhibitors (PPIs) market forecast
- Proton pump inhibitors (PPIs) market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading proton pump inhibitors (PPIs) market vendors that include Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Perrigo Co. Plc, Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., The Procter and Gamble Co., and Zydus Lifesciences Ltd.. Also, the proton pump inhibitors (PPIs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.